The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and/or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and/or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.
C07D 261/08 - Composés hétérocycliques contenant des cycles oxazole-1, 2 ou oxazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant plusieurs liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
2.
METHOD FOR STERILIZING AND FILLING CONTAINERS FOR PHARMACEUTICAL PRODUCT AND RELATED FILLING SYSTEM
The invention relates to a method for sterilizing containers and filling said containers in sterile conditions with a pharmaceutical product, comprising the steps of: - providing a plurality of internally sterile empty containers (1); - performing a filling cycle, comprising the sequential steps of o introducing a group of empty container(s) (1) into a filling enclosure (55); o sterilizing an external surface of the empty container(s) (1) by application of electron beam radiation emitted by an electron beam emitter (73); o introducing a filling needle (75) into each container body (3) and dispensing pharmaceutical product through the filling needle (75); o extracting the group of filled container(s) (1); - repeating a filling cycle with a subsequent group of empty container(s), The power of the electron beam radiation is modulated during the filling cycle between a maximum value and a minimum value, different from the maximum value and different from zero, whereby a plurality of filling cycles are carried out without switching off the electron beam emitter (73). The invention is also directed to a related filling system.
B65B 55/08 - Stérilisation des enveloppes d'emballage ou récipients avant ou pendant l'emballage par irradiation
B65B 55/10 - Stérilisation des enveloppes d'emballage ou récipients avant ou pendant l'emballage par des liquides ou des gaz
B65B 3/00 - Emballage de matériaux plastiques, de semi-liquides, de liquides ou de liquides et solides mélangés, dans des réceptacles ou récipients individuels, p. ex. dans des sacs ou sachets, boîtes, cartons, bidons ou pots
A61L 2/08 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des phénomènes physiques des radiations
3.
Dosing Regimens of SIRP Alpha Fusion Proteins for Treatment of Cancer
Dosing regimens and methods for administering SIRPaFc fusion proteins are provided. The dosing regimens and methods include both SIRPaFc monotherapies and combination therapies.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
4.
MULTI-LAYERED SYRINGE WITH A THREADED CONNECTION PART AND METHOD OF MANUFACTURING SAME
The invention relates to a syringe comprising an elongated main body having a nozzle formed at a distal end thereof and a threaded connection part at least partially surrounding the nozzle. The main body is made by co-injection molding from at least two different materials and the threaded connection part is made of a plastic material by injection molding, with the main body and the threaded connection part being overmolded one to the other. The invention also relates to a method of manufacturing such a syringe.
A61L 29/06 - Matériaux macromoléculaires obtenus autrement que par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
A61M 5/34 - Structures pour le raccordement de l'aiguille
B29C 45/16 - Fabrication d'objets multicouches ou polychromes
B29K 23/00 - Utilisation de polyalcènes comme matière de moulage
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07C 215/40 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné avec des atomes d'azote quaternisés liés à des atomes de carbone du squelette carboné
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
11.
METHOD AND APPARATUS FOR IMPROVED MAN-MACHINE INTERACTIONS
An automated smart voice-interactive platform allows users to securely register with a provider and have physical conditions monitored, in place of interacting with a variety of human workers, in a fault tolerant and adaptive manner such that interactions improve with each additional user interaction.
G10L 15/183 - Classement ou recherche de la parole utilisant une modélisation du langage naturel selon les contextes, p. ex. modèles de langage
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G10L 15/22 - Procédures utilisées pendant le processus de reconnaissance de la parole, p. ex. dialogue homme-machine
G10L 15/30 - Reconnaissance distribuée, p. ex. dans les systèmes client-serveur, pour les applications en téléphonie mobile ou réseaux
G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
12.
METHOD AND SYSTEM OF SIMULATING OPERATIONAL INTEGRITY OF A PRE-FILLED VIAL
Method and system of digitally simulating operational integrity of a pre-filled vial. The method includes simulating, in a processor of a computing system, a frictional disengaging of a stopper from the pre-filled vial responsive to a progressively decreasing ambient pressure, the pre-filled vial containing a gaseous portion that is separated from ambient air by the stopper, and generating, by the processor in accordance with the progressively decreasing ambient pressure, a measure corresponding to an aircraft altitude at which the frictional disengaging is initiated.
G06F 30/28 - Optimisation, vérification ou simulation de l’objet conçu utilisant la dynamique des fluides, p. ex. les équations de Navier-Stokes ou la dynamique des fluides numérique [DFN]
13.
METHOD AND APPARATUS FOR IMPROVED HUMAN-MACHINE INTERACTIONS
An automated smart voice-interactive platform allows users to securely register with a provider and have physical conditions monitored, in place of interacting with a variety of human workers, in a fault tolerant and adaptive manner such that interactions improve with each additional user interaction.
G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
G06T 13/40 - Animation tridimensionnelle [3D] de personnages, p. ex. d’êtres humains, d’animaux ou d’êtres virtuels
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Smoking cessation preparations; Vaccines for human use
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
Described herein are compounds of Formula (I): I and their pharmaceutically acceptable salts, wherein R1, R2, R3, Rp, A1, L1, L2, T1, T2, T3, T4, n1, t1, t2, and t3 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
19.
ORAL COMPOSITIONS/FORMULATIONS OF 2-({4-[(2S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYL-1,3-BENZODIOXOL-4-YL]PIPERIDIN-1-YL}METHYL)-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID OR A PHARMACEUTICALLY SALT THEREOF
The invention relates to immediate-release oral pharmaceutical compositions and oral controlled release swellable core technology (SCT) tablets of 2-({4-[(2S)-2-(4-chloro-2- fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid (Compound 1) or a pharmaceutically acceptable salt thereof (e.g. tris salt of Compound 1) and process of making such compositions and tablets. The present invention further relates to methods of using these compositions and tablets once daily for weight management control or for treating, e.g., T2DM, obesity, or overweight.
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Vaccines for human use
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
27.
GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF
Described herein are compounds of Formula I:
Described herein are compounds of Formula I:
Described herein are compounds of Formula I:
and their pharmaceutically acceptable salts, wherein R1, R2, R3, Rp, A1, L1, L2, T1, T2, T3, T4, n1, t1, t2, and t3 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
28.
IMPROVED METHODS FOR PRODUCING GLYCOCONJUGATES BY REDUCTIVE AMINATION IN APROTIC SOLVENT
The present disclosure relates to media and fermentation methods for polysaccharide production in bacterial cell culture. In one aspect, the disclosure relates to cell culture media comprising potassium phosphate and calcium chloride. In another aspect, the disclosure relates to a method of fermenting bacterial cell culture under pressurized conditions. The media and methods disclosed herein are useful for increasing the polysaccharide production and reducing the lag phase of a bacterial cell culture, i.e., Streptococcus pneumoniae.
The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.
A61K 31/416 - 1,2-Diazoles condensés avec des systèmes carbocycliques, p. ex. indazole
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/5386 - 1,4-Oxazines, p. ex. morpholine condensées en spiro ou formant une partie de systèmes cycliques pontés
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. loxapine, staurosporine
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07D 231/54 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 491/048 - Systèmes condensés en ortho avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène le cycle contenant de l'oxygène étant à cinq chaînons
C07D 491/056 - Systèmes condensés en ortho avec au moins deux atomes d'oxygène comme hétéro-atomes du cycle contenant de l'oxygène
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
The present invention relates to a process for the production of a conjugate vaccine comprising a preservative. The invention relates in particular to a process for the production of a conjugate vaccine where the preservative is hydrophobic and viscous (such as 2-phenoxyethanol (2-PE)).
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
44.
TMPRSS2-ERG AND RB1 AS PREDICTIVE BIOMARKERS FOR TREATMENT WITH A PARP INHIBITOR
This invention relates to methods for selecting patients having prostate cancer for treatment with a PARP inhibitor, such as talazoparib, or a pharmaceutically acceptable salt thereof, and an androgen receptor inhibitor, such as enzalutamide, or a pharmaceutically acceptable salt thereof, comprising: i) determining an ERG gene alteration status, wherein the ERG gene alteration is a TMPRSS2-ERG gene fusion/rearrangement, and/or determining an RB1 gene alteration status, from a biological sample of the prostate cancer from the subject; and ii) selecting patients with the TMPRSS2-ERG gene fusion/rearrangement and/or the RB1 gene alteration for treatment.
The invention relates to an injection device comprising a housing, a needle connection (55) for attaching a needle (61) to a cartridge (7) received in the housing (2), an injection drive mechanism (9), an electronic control system for controlling the injection drive mechanism (9) and a needle sensing feature for detecting the attachment of a needle (61) to the cartridge (7). The needle sensing feature includes a slider (13) comprising a magnetic part and an electromagnetic sensor (203) arranged within the housing (2), such that the magnetic part can move between positions remote from the electromagnetic sensor (203) and a position in the vicinity of the electromagnetic sensor (203), when the slider (13) is in its retracted position, wherein the electromagnetic sensor (203) is caused to generate a signal indicative of a needle (61) being attached to the cartridge (7).
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/24 - Seringues à ampoules, c.-à-d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p. ex. automatiques
A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
A61M 5/34 - Structures pour le raccordement de l'aiguille
The invention relates to polypeptides and RNA molecules encoding an E. coli fimbrial antigen PapG mutant. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the polypeptides, RNA molecules, RNA-LNPs and compositions thereof for the prevention of E.coli infection, including urinary tract infection.
Methods for identifying a subject eligible to receiving a therapeutic amount of a CDK4 inhibitor, predicting whether a subject is sensitive to treatment with a CDK4 inhibitor and methods of treating cancer are disclosed. The methods are based on measurement of mRNA expression, protein expression, and/or activity of cyclin-dependent kinase 6 (CDK6), cyclin E1 (CCNE1), cyclin D1 (CCND1), and/or Androgen Receptor (AR).
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
Provided herein are cells, compositions, and related methods for improved cell growth. The expression of one or more of CBS, CTH, and GNMT genes is increased. In some embodiments, nucleic acid constructs, vectors, host cells and related compositions and methods for generating and selecting cysteine prototroph cells are provided.
The invention relates to compounds of Formula I
The invention relates to compounds of Formula I
The invention relates to compounds of Formula I
and pharmaceutically acceptable salts thereof wherein R1, R2, R3, p, q, q′ and Ring A are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
A61K 31/422 - Oxazoles non condensés et contenant d'autres hétérocycles
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
50.
CDK4 INHIBITORS AND COMBINATIONS WITH CDK2 INHIBITORS OR FURTHER AGENTS FOR USE IN THE TREATMENT OF CANCER
This invention relates to therapies for treating cancers in a subject comprising a cyclin dependent kinase 4 (CDK4) inhibitor, and optionally in combination with a CDK2 or an additional anti-tumor agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.
A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
This invention relates to therapies for treating mantle cell lymphoma comprising a cyclin dependent kinase 4 (CDK4) inhibitor or a pharmaceutically acceptable salt thereof, and associated methods of treatment, pharmaceutical compositions, and uses thereof.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
57.
FORMULATIONS COMPRISING N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDE COMPOUNDS AND USES THEREOF
The present disclosure relates to compositions comprising N-substituted-dioxocyclobutenylamino-3-hydroxy-picoliamide compounds or a pharmaceutically acceptable salt or hydrate thereof, methods of preparing said compositions, and uses thereof. The compositions may be useful in the treatment of conditions ameliorated by inhibition of CC chemokine receptor 6.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and/or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and/or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
C07D 413/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use
E. coliE. coli lipopolysaccharides. In one embodiment, the O-polysaccharide molecules are conjugated to streptococcal C5a peptidase (SCP). In some embodiments, the O-polysaccharide molecules are conjugated to SCR using click chemistry.
This disclosure relates to the novel processes for the synthesis of (1H-pyrazol-5-yl)cyclopentyl carbamate compounds, to novel intermediates useful for the synthesis of (1H-pyrazol-5-yl)cyclopentyl carbamate compounds, and to the synthesis of said intermediates.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 231/14 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
The invention relates to vaccination of human subjects, in particular elderly, against bacterial infections, wherein the bacterial infection is not pneumococcal, and COVID-19 infections.
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
72.
COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE PROTECTIVE AGAINST LYME DISEASE
The present invention relates to methods of administering a composition comprising the OspA fusion proteins of SEQ ID NO: 1 (LipSI D1-S2D1), SEQ ID NO: 2 (Lip-S4D1-S3hybD1), and SEQ ID NO: 3 (Lip-S5D1-S6D1) for eliciting an immune response protective against Lyme disease in a subject, such as vaccinating a subject against Lyme disease, and for treating, preventing, and/or reducing the risk of Lyme disease.
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention discloses a novel crystalline form of ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone free base, pharmaceutical composition containing the same, preparations thereof and uses thereof.
The present invention relates to new conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
In one aspect, the present disclosure relates to an immunogenic composition comprising conjugated O-polysaccharide molecules derived from E. coli lipopolysaccharides. In one embodiment, the O-polysaccharide molecules are conjugated to streptococcal C5a peptidase (SCP). In some embodiments, the O-polysaccharide molecules are conjugated to SCP using click chemistry.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/385 - Haptènes ou antigènes, liés à des supports
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 31/14 - Antiviraux pour le traitement des virus ARN
The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and/or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use; food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth; dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use; food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth; dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides.
The present invention relates to compounds of Formula (I):
The present invention relates to compounds of Formula (I):
The present invention relates to compounds of Formula (I):
or pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R1-R16, n and p are defined herein. The novel nitrogen-linked benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth, such as cancer, in patients.
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/423 - Oxazoles condensés avec des carbocycles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Veterinary pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Veterinary pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Smoking cessation preparations; Vaccines for human use
Described are methods for producing RNA molecules in an in vitro transcription reaction. Also described are methods for producing an mRNA molecule from a circular double-stranded DNA template using an in vitro transcription reaction system wherein the in vitro transcription reaction system lacks a polyamine. Also described are in vitro transcription reaction systems comprising enzymatic 5′ capping and oligo (dT) purification.
The invention relates to a method of treating a MEK-associated tumor by administering to a subject in need thereof a therapeutically effective amount of a solid form 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
A61P 15/10 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour l'impuissance
A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 25/30 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
The invention relates to a vial for containing a pharmaceutical product comprising - a vial body (3) including a substantially cylindrical wall (7) extending along a main axis (X), a bottom wall (8) closing the cylindrical wall (7) at the bottom end thereof and a neck portion (9) coaxially extending from the cylindrical wall (7) at the upper end thereof; and - a cap assembly (5) attached to the neck portion (9) for sealingly closing the inner volume (24) of the vial body (3). The vial body (3) further includes at the bottom end thereof a flange (33) defining a cavity (35) with a non-cylindrical shape, whereby rotation of the vial (1) about the main axis (X) is prevented when the cavity is matingly engaged by a male connecting piece. The invention is also directed to a filling system suitable for filling such vials in sterile conditions with a pharmaceutical product.
B65B 3/00 - Emballage de matériaux plastiques, de semi-liquides, de liquides ou de liquides et solides mélangés, dans des réceptacles ou récipients individuels, p. ex. dans des sacs ou sachets, boîtes, cartons, bidons ou pots
The present disclosure relates to hMPV F protein mutants, nucleic acids or vectors encoding a hMPV F protein mutant, compositions comprising a hMPV F protein mutant or nucleic acid, and uses of the hMPV F protein mutants, nucleic acids or vectors, and compositions.
Described herein are GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.
C07D 207/16 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07C 229/26 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant plus d'un groupe amino lié au squelette carboné, p. ex. lysine
C07C 279/14 - Dérivés de la guanidine, c.-à-d. composés contenant le groupe les atomes d'azote liés par des liaisons simples ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes guanidine liés à des atomes de carbone acycliques d'un squelette carboné étant substitué de plus par des groupes carboxyle
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
89.
COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS
Provided herein is a compound of the Formula I:
Provided herein is a compound of the Formula I:
Provided herein is a compound of the Formula I:
or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and L are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors.
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07D 239/90 - Atomes d'oxygène avec des radicaux acycliques liés en position 2 ou 3
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
91.
COMBINATION THERAPY USING GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONIST COMPOUNDS AND GLP-1 RECEPTOR AGONIST PEPTIDES
Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause; Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause; Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Providing medical information in the field of heart disease; Providing information in the field of the diagnosis and treatment of heart diseases via a website
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Providing medical information in the field of heart disease; Providing information in the field of the diagnosis and treatment of heart diseases via a website
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of digestive disorders; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of gastrointestinal disorders; Pharmaceutical preparations for the treatment of blood disorders; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of cardiovascular disorders; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the treatment of oncological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hepatological diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause; Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of digestive disorders; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of gastrointestinal disorders; Pharmaceutical preparations for the treatment of blood disorders; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of cardiovascular disorders; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the treatment of oncological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hepatological diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause; Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of digestive disorders; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of gastrointestinal disorders; Pharmaceutical preparations for the treatment of blood disorders; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of cardiovascular disorders; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; Pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the treatment of oncological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hepatological diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause; Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations
99.
ENHANCEMENT OF CD47 BLOCKADE WITH TAXANES FOR CD47+ CANCER THERAPY
The invention provides combinations of materials and methods for disease treatment, such as CD47+ cancer treatment. The combinations include a CD47 blocking agent and a taxane.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
The invention relates to benzodiazepine pyrazolo carboxamidesand pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of invention inhibit the activity RSV N-proteins and may be useful in the treatment, prevention, suppression, and amelioration of viral infections such as RSV.
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61K 31/5365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes hétérocycliques
